

# Gastroesophageal Reflux Disease Market Report 2034: Epidemiology, Pipeline Therapies, Latest Approvals by DelveInsight

*Gastroesophageal Reflux Disease companies working in the market are Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, Arog Pharmaceuticals.*

LAS VEGAS, NV, UNITED STATES, January 13, 2025 /EINPresswire.com/ -- DelveInsight's "Gastroesophageal Reflux Disease Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Gastroesophageal Reflux Disease, historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gastroesophageal Reflux Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Gastroesophageal Reflux Disease Market Forecast](#)

Some of the key facts of the Gastroesophageal Reflux Disease Market Report:

The Gastroesophageal Reflux Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

In July 2024, Phathom Pharmaceuticals received an expanded indication for its acid suppression medication. The FDA broadened the label of Voquezna to include the treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD).

In November 2023, the FDA approved VOQUEZNA (vonoprazan) tablets in 10 mg and 20 mg doses, a pioneering potassium-competitive acid blocker (PCAB), as a new treatment option for adults. This medication is indicated for healing all grades of erosive esophagitis, commonly known as erosive GERD (gastroesophageal reflux disease). It is also approved for maintaining the healing of erosive GERD and providing relief from heartburn associated with the condition.

In May 2023, Phathom Pharmaceuticals refiled its New Drug Application (NDA) with the FDA for vonoprazan, seeking approval for the treatment of erosive gastroesophageal reflux disease (GERD), also known as erosive esophagitis.

In June 2022, Zydus Lifesciences received FDA approval to market Famotidine tablets in 20 mg and 40 mg strengths. Famotidine is a histamine H2 receptor blocker that reduces stomach acid, helping to relieve and prevent heartburn and other symptoms of acid reflux.

The market for Gastroesophageal Reflux Disease (GERD) is expected to grow significantly from 2024 to 2034, driven by increasing prevalence, aging populations, greater awareness, lifestyle changes, and advancements in treatment options. The rising healthcare expenditure and the

complications associated with GERD further highlight the growing global demand for effective management solutions.

Epidemiological data suggest that GERD is a widespread condition, though its exact prevalence varies across studies due to differences in diagnostic criteria and research methodologies.

Key challenges in GERD include the complexity of diagnosis, owing to the variability in symptoms, the need for thorough evaluation, and the difficulties in treating refractory cases or managing comorbid conditions that complicate treatment.

Several pharmaceutical companies are actively developing therapies for GERD, with Cinclus Pharma, Braintree (a part of Sebelo Pharmaceuticals), N-Zyme Biomedical Inc., and others leading the way. These companies are introducing innovative and effective treatments to address the unmet needs of GERD patients.

According to our analysis, the prevalence of GERD in North America ranges from 18% to 28%, while in Europe, it varies between 9% and 26%. These findings reflect a substantial disease burden across both regions.

Our data also reveals that GERD is more prevalent in females than in males, suggesting a potential gender difference in the occurrence of the condition. This highlights the need to consider gender-specific factors when managing and treating GERD. The higher prevalence in females may be linked to factors such as hormonal fluctuations, differences in oesophageal motility, and anatomical differences.

We observed that individuals aged 50-59 years exhibit the highest GERD prevalence, while those aged 70 and older have the lowest. This pattern is likely due to age-related changes in gastrointestinal function, lifestyle factors, and comorbidities that become more common in older populations.

Our analysis also shows that GERD in the US, similar to other regions, is mainly classified into two subtypes: Non-erosive reflux disease (NERD) and erosive esophagitis (EE). The majority of GERD cases fall under the NERD category, highlighting the importance of recognizing and managing non-erosive forms of GERD.

In France, GERD has an overall prevalence of approximately 31%. The prevalence of frequent GERD is higher in individuals over 50 years old (10%) compared to those under 50 years (6%), emphasizing the role of age as a key factor in GERD prevalence.

**Key Gastroesophageal Reflux Disease Companies:** Cinclus Pharma, Onconic Therapeutics, Renexion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, Arog Pharmaceuticals, Taiho Pharmaceutical, Cogent Biosciences, Plexxikon, and others

**Key Gastroesophageal Reflux Disease Therapies:** VOQUEZNA (vonoprazan), BLI5100 (Tegoprazan), and others

The Gastroesophageal Reflux Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroesophageal Reflux Disease pipeline products will significantly revolutionize the Gastroesophageal Reflux Disease market dynamics.

**Gastroesophageal Reflux Disease Overview**

Gastro-oesophageal reflux disease (GERD) is a chronic condition where stomach contents, including acid and bile, flow back into the oesophagus, causing symptoms such as heartburn,

regurgitation, and chest pain. This usually occurs due to dysfunction of the lower oesophageal sphincter (LES), which normally prevents the backward flow of gastric contents. Other factors contributing to GERD include hiatal hernia, impaired oesophageal motility, obesity, and certain dietary habits, such as the consumption of spicy or fatty foods, caffeine, and alcohol. GERD can present as non-erosive reflux disease (NERD), where no visible damage is seen in the oesophageal lining, or erosive oesophagitis, which involves inflammation and damage to the oesophageal tissue.

The severity of GERD symptoms can vary and may include heartburn (a burning sensation in the chest, especially after eating or lying down), regurgitation of acidic material into the mouth, difficulty swallowing (dysphagia), chest pain, and a chronic cough. These symptoms can severely affect quality of life and, if left untreated, may lead to complications such as oesophageal strictures, Barrett's oesophagus, and oesophageal adenocarcinoma.

Get a Free sample for the Gastroesophageal Reflux Disease Market Forecast, Size & Share Analysis Report:

Gastroesophageal Reflux Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastroesophageal Reflux Disease Epidemiology Segmentation:

The Gastroesophageal Reflux Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Diagnosed Prevalence of Gastroesophageal Reflux Disease in Adults

Diagnosed Prevalence of Gastroesophageal Reflux Disease in Pediatrics

Diagnosed Prevalence of Gastroesophageal Reflux Disease by Types

Diagnosed Prevalence of Gastroesophageal Reflux Disease by Location

Diagnosed Prevalence of Gastroesophageal Reflux Disease by Severity

Gastroesophageal Reflux Disease Marketed Drugs

VOQUEZNA (vonoprazan): Phathom Pharmaceuticals, Inc.

Gastroesophageal Reflux Disease Emerging Drugs

BLI5100 (Tegoprazan): Braintree/ Sebela Pharmaceuticals

Gastroesophageal Reflux Disease Therapies

VOQUEZNA (vonoprazan), BLI5100 (Tegoprazan), and others

Gastroesophageal Reflux Disease Key Companies

Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, Arog Pharmaceuticals, Taiho Pharmaceutical, Cogent Biosciences, Plexxikon, and others

Discover more about therapies set to grab major Gastroesophageal Reflux Disease market share

@ [Gastroesophageal Reflux Disease Treatment Landscape](#)

Gastroesophageal Reflux Disease Market Outlook

The management of GERD is organized into five stages, with stages I through IV focused on medical treatment and stage V involving surgical intervention. The primary goal of treatment is to reduce esophageal exposure to refluxate, alleviating symptoms, healing the esophagus, preventing complications, and maintaining remission. Most patients achieve adequate symptom control and esophageal healing through lifestyle changes and medication, making surgery unnecessary. However, surgery may be needed for those with severe symptoms, erosive esophagitis, or complications despite effective drug therapy.

Lifestyle changes play a crucial role in managing GERD at all stages. These include elevating the head of the bed, reducing fat intake, quitting smoking, cutting back on alcohol, losing weight, avoiding lying down after meals, and steering clear of large meals or trigger foods.

For patients with mild symptoms, periodic drug therapy is often used for symptom relief. This typically involves antacids, alginic acid (found in products like Gaviscon), or over-the-counter H<sub>2</sub>-receptor blockers.

- Antacids and Alginic Acid: Antacids provide quick relief by increasing the pH of gastric refluxate, but they are not sufficient for healing the esophagus. Alginic acid, found in some antacid products, forms a mechanical barrier that reduces reflux exposure to the esophagus.

- Over-the-Counter H<sub>2</sub>-Receptor Blockers: These drugs are used to prevent and relieve symptoms like heartburn and indigestion. They provide longer-lasting relief than antacids, though they act more slowly, making them better suited for preventing GERD symptoms.

For more persistent cases, proton pump inhibitors (PPIs) like DEXILANT (dexlansoprazole) are used to treat erosive esophagitis and heartburn from non-erosive GERD.

In patients with moderate to severe GERD, or documented erosive esophagitis, scheduled pharmacologic therapy is necessary. This involves the regular use of drugs to suppress gastric acid, reduce reflux symptoms, promote healing, and maintain remission.

Surgery is considered for patients who do not respond to medical treatments or develop complications. Non-compliance, cost issues, relapse after stopping medication, or ongoing symptoms despite continuous use of drugs can lead to surgical intervention. Surgery may also be needed for patients with complications such as large hiatal hernias, Barrett's esophagus, severe esophagitis, recurrent strictures, or significant pulmonary symptoms.

Scope of the Gastroesophageal Reflux Disease Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Gastroesophageal Reflux Disease Companies: Cinclus Pharma, Onconic Therapeutics, Renexion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, Arog Pharmaceuticals, Taiho Pharmaceutical, Cogent Biosciences, Plexxikon, and others

Key Gastroesophageal Reflux Disease Therapies: VOQUEZNA (vonoprazan), BLI5100 (Tegoprazan), and others

Gastroesophageal Reflux Disease Therapeutic Assessment: Gastroesophageal Reflux Disease current marketed and Gastroesophageal Reflux Disease emerging therapies

Gastroesophageal Reflux Disease Market Dynamics: Gastroesophageal Reflux Disease market drivers and Gastroesophageal Reflux Disease market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Gastroesophageal Reflux Disease Unmet Needs, KOL's views, Analyst's views, Gastroesophageal Reflux Disease Market Access and Reimbursement

To know more about Gastroesophageal Reflux Disease companies working in the treatment market, visit @ [Gastroesophageal Reflux Disease Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Gastroesophageal Reflux Disease Market Report Introduction
2. Executive Summary for Gastroesophageal Reflux Disease
3. SWOT analysis of Gastroesophageal Reflux Disease
4. Gastroesophageal Reflux Disease Patient Share (%) Overview at a Glance
5. Gastroesophageal Reflux Disease Market Overview at a Glance
6. Gastroesophageal Reflux Disease Disease Background and Overview
7. Gastroesophageal Reflux Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Gastroesophageal Reflux Disease
9. Gastroesophageal Reflux Disease Current Treatment and Medical Practices
10. Gastroesophageal Reflux Disease Unmet Needs
11. Gastroesophageal Reflux Disease Emerging Therapies
12. Gastroesophageal Reflux Disease Market Outlook
13. Country-Wise Gastroesophageal Reflux Disease Market Analysis (2020–2034)
14. Gastroesophageal Reflux Disease Market Access and Reimbursement of Therapies
15. Gastroesophageal Reflux Disease Market Drivers
16. Gastroesophageal Reflux Disease Market Barriers
17. Gastroesophageal Reflux Disease Appendix
18. Gastroesophageal Reflux Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Gastroesophageal Reflux Disease Pipeline

"Gastroesophageal Reflux Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Gastroesophageal Reflux Disease market. A detailed picture of the Gastroesophageal Reflux Disease pipeline landscape is provided, which includes the disease overview and Gastroesophageal Reflux Disease treatment guidelines.

Gastroesophageal Reflux Disease Epidemiology

DelveInsight's 'Gastroesophageal Reflux Disease Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Gastroesophageal Reflux Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market  
About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Kritika Rehani

DelveInsight Business Research LLP

+1 469-945-7679

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/776507278>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.